S. Munjal

发表

Human factors validation study of 3 mg sumatriptan autoinjector, for migraine patients

A. Andre, R. Kumar, E. Brand-Schieber, 2016, Medical devices.

Comorbid and co-occurring conditions in migraine and associated risk of increasing headache pain intensity and headache frequency: results of the migraine in America symptoms and treatment (MAST) study

R. Lipton, D. Dodick, S. Munjal, 2020, The Journal of Headache and Pain.

Most Bothersome Symptom in Persons With Migraine: Results From the Migraine in America Symptoms and Treatment (MAST) Study

R. Lipton, D. Dodick, S. Munjal, 2019, Headache.

Pharmacokinetic Characterization and Dose Selection of a Novel Sumatriptan Nasal Spray Formulation, DFN‐02

A. Gautam, S. Munjal, A. Pal, 2017, Journal of clinical pharmacology.

Randomized, double-blind, crossover study comparing DFN-11 injection (3 mg subcutaneous sumatriptan) with 6 mg subcutaneous sumatriptan for the treatment of rapidly-escalating attacks of episodic migraine

R. Cady, E. Brand-Schieber, S. Munjal, 2017, The Journal of Headache and Pain.

Predictors of allodynia in persons with migraine: Results from the Migraine in America Symptoms and Treatment (MAST) study

R. Lipton, D. Dodick, S. Munjal, 2019, Cephalalgia : an international journal of headache.

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Tolerability, and Safety of Celecoxib Oral Solution (ELYXYB) in Acute Treatment of Episodic Migraine with or without Aura

R. Lipton, S. Tepper, S. Munjal, 2021, Journal of pain research.

2-deoxy-d-glucose as an adjunct to standard of care in the medical management of COVID-19: a proof-of-concept and dose-ranging randomised phase II clinical trial

Srinivas H Shenoy, S. Chandna, A. Bhatt, 2022, BMC Infectious Diseases.

Population estimates for biomarkers of exposure to cigarette smoke in adult U.S. cigarette smokers.

S. Feng, Q. Liang, S. Munjal, 2009, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.

2-Deoxy-D-Glucose as an Adjunct to Standard of Care in the Medical Management of COVID-19: A Proof-of-Concept & Dose-Ranging Randomised Clinical Trial

S. Chandna, A. Bhatt, Vijayakumar Chinnadurai, 2021, medRxiv.

Safety and pharmacokinetics of single and multiple intravenous bolus doses of diclofenac sodium compared with oral diclofenac potassium 50 mg: A randomized, parallel‐group, single‐center study in healthy subjects

A. Gautam, S. Munjal, F. Okumu, 2016, Journal of clinical pharmacology.

Efficacy and safety of DFN-11 (sumatriptan injection, 3 mg) in adults with episodic migraine: an 8-week open-label extension study

A. Rapoport, E. Brand-Schieber, S. Munjal, 2018, The journal of headache and pain.

Efficacy, Tolerability, and Safety of DFN‐15 (Celecoxib Oral Solution, 25 mg/mL) in the Acute Treatment of Episodic Migraine: A Randomized, Double‐Blind, Placebo‐Controlled Study

R. Lipton, D. Dodick, S. Tepper, 2019, Headache.

A multicenter, open-label, long-term safety and tolerability study of DFN-02, an intranasal spray of sumatriptan 10 mg plus permeation enhancer DDM, for the acute treatment of episodic migraine

R. Cady, A. Rapoport, E. Brand-Schieber, 2017, The Journal of Headache and Pain.

Heart Rate Variability Increases With Reductions in Cigarette Smoke Exposure After 3 Days

S. Munjal, M. Unverdorben, H. Roethig, 2009, Journal of cardiovascular pharmacology and therapeutics.

Favipiravir In Adults with Moderate to Severe COVID-19: A Phase 3 Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial.

S. Munjal, R. Kaszynski, S. Al Youha, 2021, medRxiv.

Burden of increasing opioid use in the treatment of migraine: Results from the Migraine in America Symptoms and Treatment Study

R. Lipton, D. Dodick, S. Munjal, 2020, Headache.

DFN‐02 (Sumatriptan 10 mg With a Permeation Enhancer) Nasal Spray vs Placebo in the Acute Treatment of Migraine: A Double‐Blind, Placebo‐Controlled Study

R. Lipton, A. Rapoport, E. Brand-Schieber, 2018, Headache.

The relationship between smoking machine derived tar yields and biomarkers of exposure in adult cigarette smokers in the US.

Q. Liang, S. Munjal, Paul E Mendes, 2009, Regulatory toxicology and pharmacology : RTP.

Pharmacokinetics of DFN-15, a Novel Oral Solution of Celecoxib, Versus Celecoxib 400-mg Capsules: A Randomized Crossover Study in Fasting Healthy Volunteers

A. Gautam, S. Munjal, M. Gopalakrishnan, 2017, Clinical Drug Investigation.

Migraine in America Symptoms and Treatment (MAST) Study: Baseline Study Methods, Treatment Patterns, and Gender Differences

R. Lipton, D. Dodick, S. Munjal, 2018, Headache.

Effects of Different Levels of Cigarette Smoke Exposure on Prognostic Heart Rate and Rate—Pressure-Product Parameters

S. Munjal, M. Unverdorben, L. Potgieter, 2008, Journal of cardiovascular pharmacology and therapeutics.

Factors associated with acute medication overuse in people with migraine: results from the 2017 migraine in America symptoms and treatment (MAST) study

R. Lipton, D. Dodick, S. Munjal, 2018, The journal of headache and pain.

Unmet Acute Treatment Needs From the 2017 Migraine in America Symptoms and Treatment Study

R. Lipton, D. Dodick, S. Munjal, 2019, Headache.

DFN-02, Sumatriptan 10 mg Nasal Spray with Permeation Enhancer, for the Acute Treatment of Migraine: A Randomized, Double-Blind, Placebo-Controlled Study Assessing Functional Disability and Subject Satisfaction with Treatment

R. Lipton, A. Rapoport, S. Munjal, 2019, CNS Drugs.

Subcutaneous sumatriptan delivery devices: comparative ease of use and preference among migraineurs

Rajesh Kumar, Anthony D Andre, A. Andre, 2017, Patient preference and adherence.

Treatment patterns of patients diagnosed with major headache disorders: A retrospective claims analysis

S. Silberstein, B. Yue, S. Munjal, 2020 .

Allodynia Is Associated With Initial and Sustained Response to Acute Migraine Treatment: Results from the American Migraine Prevalence and Prevention Study

R. Burstein, S. Munjal, D. Buse, 2017, Headache.

A Randomized Trial Comparing the Pharmacokinetics, Safety, and Tolerability of DFN‐02, an Intranasal Sumatriptan Spray Containing a Permeation Enhancer, With Intranasal and Subcutaneous Sumatriptan in Healthy Adults

A. Gautam, S. Munjal, D. Fisher, 2016, Headache.

Predicting Inadequate Response to Acute Migraine Medication: Results From the American Migraine Prevalence and Prevention (AMPP) Study

S. Munjal, D. Buse, K. Fanning, 2016, Headache.

Acute Treatment of Migraine with Celecoxib Oral Solution: Results of a Randomized, Placebo-Controlled Clinical Trial

R. Lipton, D. Dodick, S. Tepper, 2021, Journal of pain research.

Tepilamide Fumarate (PPC-06) Extended Release Tablets in Patients with Moderate-to-Severe Plaque Psoriasis: Safety and Efficacy Results from the Randomized, Double-blind, Placebo-controlled AFFIRM Study.

Srinivas H Shenoy, M. Lebwohl, K. Reich, 2022, The Journal of clinical and aesthetic dermatology.

Efficacy and safety of DFN-15, an oral liquid formulation of celecoxib, in adults with migraine: a multicenter, randomized, placebo-controlled, double-blind, crossover study

S. Munjal, Alix Bennett, 2017, Neuropsychiatric disease and treatment.

Triptan Use and Discontinuation in a Representative Sample of Persons With Migraine: Results From Migraine in America Symptoms and Treatment (MAST) Study (P4.10-019)

R. Lipton, D. Dodick, S. Munjal, 2019 .

Efficacy and safety of DFN-11 (sumatriptan injection, 3 mg) in adults with episodic migraine: a multicenter, randomized, double-blind, placebo-controlled study

A. Rapoport, S. Munjal, S. Landy, 2018, The journal of headache and pain.

Acute effects of cigarette smoking on pulmonary function.

S. Munjal, H. Roethig, A. Mostert, 2010, Regulatory toxicology and pharmacology : RTP.

Population estimates for biomarkers of exposure to cigarette smoke in adult U.S. cigarette smokers.

S. Feng, Q. Liang, S. Munjal, 2009, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.